INO-4800 – A DNA based vaccine against COVID-19

In this talk, Dr Broderick introduces us to the INO-4800 SARS-CoV-2 DNA vaccine and shares Phase I and II clinical trial data. The vaccine is shown to induce broad antibody and persistent CD8 T cell responses (including T cell responses targeting Variants of Concern).

Kate Broderick received her Ph.D. from the University of Glasgow, Scotland, and conducted post-doctoral research at the University of California, San Diego. She joined INOVIO in 2006, where she currently leads a diverse research group focused on enhanced delivery techniques for gene-based therapeutics as the Senior Vice President, Preclinical R&D. She is a co-inventor on multiple patents related to DNA vaccine delivery and has served as a principal investigator on grants, awards, and contracts from leading government agencies and not-for-profit organizations, including the Bill and Melinda Gates Foundation, the National Institutes of Health, the U.S. Department of Defense, the Small Business Innovation Research program, and including a $56M award from the Coalition for Epidemic Preparedness Innovations (CEPI). In 2018, Dr. Broderick was named Business Women of the Year by San Diego Business Journal. Her particular area of focus is infectious diseases with an emphasis on emerging targets and those from a bio-threat potential. Most recently, Dr. Broderick led the teams that brought the first in human Lassa fever vaccine into the clinic as well as advanced the development of a DNA vaccine for the MERS virus and she is responsible for driving the development of a DNA vaccine for COVID-19.